News & Updates

Show Multimedia Only
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Nov 2022 byRoshini Claire Anthony

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Lower all-cause death, fewer HF events with empagliflozin in acute HF
25 Nov 2022
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022

A significant number of patients with infective endocarditis have been found to have antineutrophil cytoplasmic antibody (ANCA), which is associated with longer disease duration, more frequent purpura, and kidney involvement, results of a study has shown.

ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022
Low use of CVD prevention strategies in people with HIV
Low use of CVD prevention strategies in people with HIV
18 Nov 2022 byRoshini Claire Anthony

There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.

Low use of CVD prevention strategies in people with HIV
18 Nov 2022